The group's principal activities are to develop pharmaceutical products based on carbohydrate compounds and related technologies. The group has developed a drug called gcs-100 aimed at treating multiple forms of cancer. It also develops two agricultural products and continues to seek strategic alternatives, including the sale, of its agricultural product business area. It conducts its business through its three wholly owned subsidiaries, international gene group, inc, safescience products, inc and safescience newco ltd. International gene group, inc. ("Igg") develops human therapeutics. Igg is focused on developing gcs-100, a complex carbohydrate intended to fight cancerous tumors and metastasis. Safescience products develops agriculture products and markets chemically safe consumer and commercial products. The group terminated joint venture with elan international services ltd.
